

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8523 – BD/BARD

SECTION 1.2

Description of the concentration

1. Pursuant to an agreement and plan of merger entered into on 23 April 2017 by and among Becton, Dickinson and Company (“BD”), Lambda Corp., a wholly owned subsidiary of BD (“Merger Corp”), and C. R. Bard, Inc. (“Bard”), upon the fulfilment of certain conditions, Merger Corp shall be merged with and into Bard, with Bard to continue as the surviving corporation and a wholly owned subsidiary of BD.
2. BD a New Jersey (U.S.) corporation, is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. BD partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
3. Bard, a New Jersey (U.S.) corporation, and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. Currently, Bard sells products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis, and offer vascular, urology, oncology and surgical specialty products.